Pharma, biotech, medical device, and health professionals are invited to attend the 2nd Investigator-Initiated Trials Summit on November 2-3, 2022 in Philadelphia. This summit provides an unmatched opportunity for discussions on engaging investigators, aligning research with organizational goals, designing and executing the best study protocols, and fostering collaboration.
Attendees can learn ways of managing costs and securing operational support in investigator-initiated trials. Further, attendees can learn and network at three events for the cost of just one event ticket, since their registration also gains them entry to the 6th Digital Strategy & Innovation for Medical Affairs or…
To learn more, please visit https://ibn.fm/4VuBr
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.